Drug Trial Radar · NCT00171210
An Extension Study of Iron Chelation Therapy With Deferasirox (ICL670) in β-thalassemia Patients With Transfusional Iron Overload
Last checked: Nov 20, 2026Latest source record: May 30, 2011 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
506
Actual
Start
Oct 2004
Primary completion
Apr 2008
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Sep 15, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 2 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A 1-year randomized Phase III core trial (NCT00061750) using deferoxamine as the comparator was conducted to investigate the efficacy of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older. Patients who successfully completed this main trial may continue in this extension trial to receive chelation therapy with deferasirox for an additional 4 years. The objective of this study is to assess the efficacy and long-term safety of deferasirox in regularly transfused patients with β-thalassemia 2 years of age and older.
Conditions
- Transfusional Iron Overload in β-thalassemia
Interventions
DeferasiroxDrug
Tablets taken orally once a day.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long Term Safety and Tolerability Profile of ICL670 Based on the Number of Participants Who Experienced Any Adverse EventTime frame: up to 5 years
Locations
49 sites in 12 countries. Site status is shown where the registry gives one.
Children's Hospital Los Angeles
Los Angeles, California
Children's Hospital and Research Center at Oakland
Oakland, California
Stanford Hospital, Division of Oncology
Stanford, California
Children's Memorial Hospital
Chicago, Illinois
Children's Hospital Boston, Dept of Hematology
Boston, Massachusetts
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania
Novartis Investigative Site
Buenos Aires, Argentina
Novartis Investigative Site
Córdoba, Argentina
Novartis Investigative Site
Brussels, Belgium
Novartis Investigative Site
Laken, Belgium
Novartis Investigative Site
Liège, Belgium
Novartis Investigative Site
Mons, Belgium
Novartis Investigative Site
Campinas, Brazil
Novartis Investigative Site
São Paulo, Brazil
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Toronto, Canada
Novartis Investigative Site
Créteil, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Pierre-Bénite, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Düsseldorf, Germany
Novartis Investigative Site
Frankfurt, Germany
Novartis Investigative Site
Hamburg, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Athens, Greece
Novartis Investigative Site
Ioannina, Greece
Novartis Investigative Site
Pátrai, Greece
Novartis Investigative Site
Thessaloniki, Greece
Novartis Investigative Site
Brindisi, Italy
Novartis Investigative Site
Cagliari, Italy
Novartis Investigative Site
Catania, Italy
Novartis Investigative Site
Ferrara, Italy
Novartis Investigative Site
Genova, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
Monza, Italy
Novartis Investigative Site
Naples, Italy
Novartis Investigative Site
Palermo, Italy
Novartis Investigative Site
Pavia, Italy
Novartis Investigative Site
Roma, Italy
Showing 40 of 49 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.